Clinical trial · Observational
Adolescent Polycystic Ovary Syndrome on a Low-carbohydrate Diet
Effect of a Low-carbohydrate Diet on Outcomes According to Phenotype in Juvenile Polycystic Ovary Syndrome
NCT06429618CI-TRIAL-00086572PCOScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study was to investigate the changes in the clinical and biochemical parameters of adolescents on a low-carbohydrate diet in relation to their PCOS phenotype in the 3rd trimester.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adolescent Behavior | — | UNRESOLVED | — |
| Diet Habit | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Low carbonhydrate diet | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Phenotype A
- description
- PHENOTYPE A: Hyperandrogenism + Ovulatory Dysfunction + PCOM
- interventionNames
- Dietary Supplement: Low carbonhydrate diet
- label
- Phenotype B
- description
- PHENOTYPE B: HA+OD
- interventionNames
- Dietary Supplement: Low carbonhydrate diet
- label
- Phenotype C
- description
- PHENOTYPE C: HA+PCOM
- interventionNames
- Dietary Supplement: Low carbonhydrate diet
- label
- Phenotype D
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 12 Years
- Maximum age
- 24 Years
Show eligibility criteria text
Inclusion Criteria: * at least 1 year has passed since menarche * under 24 years old * patients who have not received an oral contraceptive method and have given verbal and written informed consent will be included. Exclusion Criteria: * over 24 years old * hyperprolactinemia, Cushing's syndrome, congenital adrenal hyperplasia, thyroid diseases * neuromuscular, liver, pancreatic or gastrointestinal diseases * hormonal medication such as antiandrogens, antidiabetics, glucocorticoids, insulin sensitizers or lipid regulators
References
Publications (2)
- BACKGROUNDJoham AE, Pena AS. Polycystic Ovary Syndrome in Adolescence. Semin Reprod Med. 2022 Mar;40(1-02):e1-e8. doi: 10.1055/s-0042-1757138. Epub 2022 Sep 12. PMID 36096151
- RESULTBozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016 Dec;31(12):2841-2855. doi: 10.1093/humrep/dew218. Epub 2016 Sep 22. PMID 27664216